NeurAxis Reports Q4 Net Loss of $1.7M
Reports Q4 net loss ($1.7M), up 18% vs. ($1.4M) in 4Q24. CEO Brian Carrico commented: "We believe NeurAxis has entered a new phase of its growth trajectory. With the Category I CPT code now in effect with positive policy coverage for more than 100 million covered lives, the foundation for scalable adoption of IB-Stim is firmly in place, and the opportunity in front of us is significantly easier for the market to understand. Our highest priority remains expanding medical policy coverage across the payer landscape, as each additional coverage win meaningfully increases patient access and reduces friction for providers. In parallel, our internal prior-authorization team continues to expand, helping hospital partners streamline reimbursement and increase confidence in adopting IB-Stim. The early part of 2026 has been focused on deploying our commercial strategy, learning from real-world utilization, and identifying the key drivers that accelerate adoption. With those insights now in hand and the reimbursement framework established, we believe we are positioned at the beginning of a multi-year growth cycle, with our focus squarely on disciplined execution and scaling utilization nationwide."
Trade with 70% Backtested Accuracy
Analyst Views on NRXS
About NRXS
About the author
Neuraxis Inc Reports Q4 2025 Earnings with Mixed Results
- Significant Revenue Growth: Neuraxis Inc reported revenues of $968,000 for Q4 2025, a 27% increase from $761,000 in Q4 2024, marking the sixth consecutive quarter of double-digit growth, indicating strong market expansion potential.
- Gross Margin Decline: Despite revenue growth, the gross margin for Q4 decreased to 85.4% from 86.4% in Q4 2024, primarily due to reserves for excess and obsolete inventory, which may impact future profitability.
- Increased Net Loss: The company reported a net loss of $1.7 million for Q4 2025, an 18% increase compared to the same period in 2024, reflecting rising operating expenses of $2.5 million, highlighting challenges in cost control.
- Strong Cash Flow Position: Neuraxis Inc ended 2025 with $5 million in cash on hand and a free cash flow of $2 million, exceeding the quarterly burn rate of $1.5 million, demonstrating robust financial management.
NeurAxis Reports Q4 2025 Financial Results
- Increased Net Loss: NeurAxis reported a net loss of $1.7 million in Q4 2025, an 18% increase from $1.4 million in Q4 2024, primarily due to higher operating losses, indicating challenges in cost management.
- Revenue Performance: The revenue for the quarter stood at $0.97 million; while specific growth figures were not disclosed, the revenue level suggests insufficient competitiveness in the market, potentially impacting future financing capabilities.
- Impact of Operating Loss: The increase in operating losses puts pressure on NeurAxis's financial condition, which may lead to decreased investor confidence in the company's future profitability, thereby affecting stock performance.
- Market Reaction Expectations: Following the earnings report, market reactions to NeurAxis may lean negative, prompting investors to closely monitor how the company addresses ongoing financial challenges and its future strategic adjustments.
Meta Platforms Sees 3.6% Stock Growth Driven by User Engagement
- User Growth: Meta Platforms has experienced steady user growth over the past year, particularly in the Asia-Pacific region, leading to a 3.6% stock increase, outperforming the 1.1% growth of the Internet - Software industry, which enhances its competitive position.
- AI Application: By leveraging artificial intelligence to improve the effectiveness of its platform services, Meta now reaches over 3.54 billion daily users, boosting its appeal to advertisers and is expected to drive future revenue growth.
- Investment Plans: Meta plans to significantly increase investments in advanced AI models over the next few years, although the monetization of these AI services may take considerable time, posing challenges to the company's future profitability.
- Market Performance: While Meta's stock performance has been strong, attention must be paid to its competitive edge in the advertising market and the monetization of AI services to ensure sustained growth and investor confidence.
NeurAxis Secures Major Medical Policy Coverage for PENFS, Impacting 45 Million Members
- Policy Coverage Expansion: NeurAxis announced that its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, has received medical policy coverage from a major national health insurer, impacting approximately 45 million health plan members and significantly enhancing the therapy's market recognition.
- Unique Treatment Solution: IB-Stim is an FDA-cleared non-invasive device specifically designed for treating functional abdominal pain in patients aged 8 and older, addressing a significant unmet medical need in pediatric functional dyspepsia treatment.
- Revenue Growth Potential: With the implementation of a Category I CPT code effective January 1, 2026, NeurAxis is positioned for substantial revenue growth and margin expansion, further solidifying its leadership in the medical technology sector.
- Increased Clinical Recognition: The company is aggressively working to secure additional coverage from large national insurers, indicating the growing recognition of IB-Stim as a necessary, evidence-based therapy for pediatric gastrointestinal disorders.
NeurAxis Prepares for 2026 Commercial Launch Amid Ongoing Double-Digit Growth and Approaching CPT Code Milestone
Management Insights: NeurAxis, Inc. is focused on executing its commercialization strategy for IB-Stim and RED, with a priority on securing medical policy coverage ahead of the new Category 1 CPT code effective January 1, 2026. The company is expanding its market opportunities and has seen positive payer momentum, with approximately 55 million covered lives.
Financial Performance: In Q3 2025, NeurAxis reported revenues of $811,000, a 22% increase year-over-year, and unit deliveries rose by 38%. However, operating expenses increased significantly, leading to an operating loss of $2.1 million, reflecting ongoing investments in sales and marketing.
Outlook and Growth Strategy: Management anticipates continued revenue growth into Q4 2025, driven by strong demand from healthcare providers and patients. They are implementing a three-pronged commercial plan for IB-Stim and addressing challenges in the adoption of RED due to changes in physician practice habits.
Risks and Concerns: The company acknowledges potential risks related to slow payer adoption and the challenges of changing physician practices for RED. Operating expenses and cash burn remain concerns, but management is focused on cost control while preparing for anticipated growth catalysts in 2026.
NeurAxis Inc Reports Increased Losses in Q3
- Earnings Overview: NeurAxis Inc reported a third-quarter loss of $2.12 million, an increase from a loss of $1.76 million in the same period last year.
- Revenue Growth: The company's revenue rose by 20.9% to $0.81 million, compared to $0.67 million in the previous year.
Neuraxis Inc Reports Q4 2025 Earnings with Mixed Results
- Significant Revenue Growth: Neuraxis Inc reported revenues of $968,000 for Q4 2025, a 27% increase from $761,000 in Q4 2024, marking the sixth consecutive quarter of double-digit growth, indicating strong market expansion potential.
- Gross Margin Decline: Despite revenue growth, the gross margin for Q4 decreased to 85.4% from 86.4% in Q4 2024, primarily due to reserves for excess and obsolete inventory, which may impact future profitability.
- Increased Net Loss: The company reported a net loss of $1.7 million for Q4 2025, an 18% increase compared to the same period in 2024, reflecting rising operating expenses of $2.5 million, highlighting challenges in cost control.
- Strong Cash Flow Position: Neuraxis Inc ended 2025 with $5 million in cash on hand and a free cash flow of $2 million, exceeding the quarterly burn rate of $1.5 million, demonstrating robust financial management.
NeurAxis Reports Q4 2025 Financial Results
- Increased Net Loss: NeurAxis reported a net loss of $1.7 million in Q4 2025, an 18% increase from $1.4 million in Q4 2024, primarily due to higher operating losses, indicating challenges in cost management.
- Revenue Performance: The revenue for the quarter stood at $0.97 million; while specific growth figures were not disclosed, the revenue level suggests insufficient competitiveness in the market, potentially impacting future financing capabilities.
- Impact of Operating Loss: The increase in operating losses puts pressure on NeurAxis's financial condition, which may lead to decreased investor confidence in the company's future profitability, thereby affecting stock performance.
- Market Reaction Expectations: Following the earnings report, market reactions to NeurAxis may lean negative, prompting investors to closely monitor how the company addresses ongoing financial challenges and its future strategic adjustments.
Meta Platforms Sees 3.6% Stock Growth Driven by User Engagement
- User Growth: Meta Platforms has experienced steady user growth over the past year, particularly in the Asia-Pacific region, leading to a 3.6% stock increase, outperforming the 1.1% growth of the Internet - Software industry, which enhances its competitive position.
- AI Application: By leveraging artificial intelligence to improve the effectiveness of its platform services, Meta now reaches over 3.54 billion daily users, boosting its appeal to advertisers and is expected to drive future revenue growth.
- Investment Plans: Meta plans to significantly increase investments in advanced AI models over the next few years, although the monetization of these AI services may take considerable time, posing challenges to the company's future profitability.
- Market Performance: While Meta's stock performance has been strong, attention must be paid to its competitive edge in the advertising market and the monetization of AI services to ensure sustained growth and investor confidence.
NeurAxis Secures Major Medical Policy Coverage for PENFS, Impacting 45 Million Members
- Policy Coverage Expansion: NeurAxis announced that its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, has received medical policy coverage from a major national health insurer, impacting approximately 45 million health plan members and significantly enhancing the therapy's market recognition.
- Unique Treatment Solution: IB-Stim is an FDA-cleared non-invasive device specifically designed for treating functional abdominal pain in patients aged 8 and older, addressing a significant unmet medical need in pediatric functional dyspepsia treatment.
- Revenue Growth Potential: With the implementation of a Category I CPT code effective January 1, 2026, NeurAxis is positioned for substantial revenue growth and margin expansion, further solidifying its leadership in the medical technology sector.
- Increased Clinical Recognition: The company is aggressively working to secure additional coverage from large national insurers, indicating the growing recognition of IB-Stim as a necessary, evidence-based therapy for pediatric gastrointestinal disorders.
NeurAxis Prepares for 2026 Commercial Launch Amid Ongoing Double-Digit Growth and Approaching CPT Code Milestone
Management Insights: NeurAxis, Inc. is focused on executing its commercialization strategy for IB-Stim and RED, with a priority on securing medical policy coverage ahead of the new Category 1 CPT code effective January 1, 2026. The company is expanding its market opportunities and has seen positive payer momentum, with approximately 55 million covered lives.
Financial Performance: In Q3 2025, NeurAxis reported revenues of $811,000, a 22% increase year-over-year, and unit deliveries rose by 38%. However, operating expenses increased significantly, leading to an operating loss of $2.1 million, reflecting ongoing investments in sales and marketing.
Outlook and Growth Strategy: Management anticipates continued revenue growth into Q4 2025, driven by strong demand from healthcare providers and patients. They are implementing a three-pronged commercial plan for IB-Stim and addressing challenges in the adoption of RED due to changes in physician practice habits.
Risks and Concerns: The company acknowledges potential risks related to slow payer adoption and the challenges of changing physician practices for RED. Operating expenses and cash burn remain concerns, but management is focused on cost control while preparing for anticipated growth catalysts in 2026.
NeurAxis Inc Reports Increased Losses in Q3
- Earnings Overview: NeurAxis Inc reported a third-quarter loss of $2.12 million, an increase from a loss of $1.76 million in the same period last year.
- Revenue Growth: The company's revenue rose by 20.9% to $0.81 million, compared to $0.67 million in the previous year.
